December Fund 3, Nikkei Fund 3 and Pureun Fund 1 cancelled the acquisition of 23.85% stake in Lumimicro Co., Ltd from Osung Advanced Materials Co., Ltd. and S-MAC CO., Ltd..
November 18, 2020
Share
December Fund 3, Nikkei Fund 3 and Pureun Fund 1 entered into a transaction to acquire 23.85% stake in Lumimicro Co., Ltd (KOSDAQ:A082800) from Osung Advanced Materials Co., Ltd. (KOSDAQ:A052420) and S-MAC CO., Ltd. (KOSDAQ:A097780) for KRW 39.8 billion on November 18, 2019. The buyers will purchase 22.09 million shares at KRW 1800 per share. Osung Advanced Materials Co., Ltd. will dispose 3.56 million shares and S-MAC CO., Ltd. will dispose 18.52 million shares. The buyers will also pay KRW 10.25 billion for bond. A down payment of KRW 5 billion will be paid on November 18, 2019, KRW 15 billion will be paid a day before the general shareholders' meeting and remaining KRW 30 billion on January 17, 2020. Post completion of the transaction, Osung Advanced Materials Co., Ltd. will hold 2.8% stake and S-MAC CO., Ltd. will hold 9.04% stake in Lumimicro Co., Ltd. The transaction is expected to complete on December 3, 2019. As of January 17, 2020, the transaction is expected to close on January 17, 2020.
December Fund 3, Nikkei Fund 3 and Pureun Fund 1 cancelled the acquisition of 23.85% stake in Lumimicro Co., Ltd (KOSDAQ:A082800) from Osung Advanced Materials Co., Ltd. (KOSDAQ:A052420) and S-MAC CO., Ltd. (KOSDAQ:A097780) on November 18, 2020.
Vivozon Pharmaceutical Co Ltd , formerly Vivozon Healthcare Inc, is a Korea-based company mainly engaged in the manufacture and sale of finished pharmaceutical products. The Company operates its business through three segments. The Pharmaceutical Business segment is engaged in the manufacture and sale of finished medicines such as external skin preparations, antipyretic analgesic, anti-inflammatory drugs and antidiabetic drugs. The Optical Business segment is engaged in the manufacture and sale of finished products and lighting module sets such as general lighting and automotive lighting using light emitting diode (LED) light sources. The Cosmetics Business segment is engaged in the manufacture and sale of cosmetics and cosmetic ingredients.
December Fund 3, Nikkei Fund 3 and Pureun Fund 1 cancelled the acquisition of 23.85% stake in Lumimicro Co., Ltd from Osung Advanced Materials Co., Ltd. and S-MAC CO., Ltd..
VIVOZON PHARMACEUTICAL CO., LTD. 
